试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-27
The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty
编号:NCT02553122登记状态:入组前撤回企业 / 申办者:Montefiore Medical Center
药物 / 成分:Evicel、tourniquet
登记的停止原因(原文):Data has been published on this study (this would have been a duplicate study)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-27
Efficacy of Sildenafil in Preterm Preeclampsia
编号:NCT02782559登记状态:入组前撤回企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:Sildenafil、Placebo
登记的停止原因(原文):difficulties acquiring the drug and funding for the drug
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-27
Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask
编号:NCT03009877登记状态:入组前撤回企业 / 申办者:Montefiore Medical Center
药物 / 成分:Optiflow F&P 850™ System、facemask、Rocuronium、Propofol
登记的停止原因(原文):withdrawn prior to IRB approval
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
编号:NCT03222089登记状态:入组前撤回企业 / 申办者:Fujian Cancer Hospital
药物 / 成分:Irinotecan、Oxaliplatin、Levoleucovorin、5-FU
登记的停止原因(原文):Another study enrolling the similar group of patient are ongoing
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-23
Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants
编号:NCT03035734登记状态:入组前撤回企业 / 申办者:Bristol-Myers Squibb
药物 / 成分:BMS-986141 Form A Tablet、BMS-986141 Form B tablet (low dose)、BMS-986141 Form B tablet (high dose)
登记的停止原因(原文):Business objectives have changed
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-22
The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients
编号:NCT02269696登记状态:入组前撤回企业 / 申办者:Kuopio University Hospital
药物 / 成分:Metoprolol、Normal saline
登记的停止原因(原文):Withdrawn
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-22
SMOFLipid in Patients Who Are Intralipid Intolerant
编号:NCT03054948登记状态:入组前撤回企业 / 申办者:Mayo Clinic
药物 / 成分:SMOFLipid、Standard therapy
登记的停止原因(原文):Redesign of study protocol.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-22
Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block for Tooth Extraction
编号:NCT03225326登记状态:入组前撤回企业 / 申办者:University of Belgrade
药物 / 成分:Computer controlled 4% articaine delivery by Anaeject、Conventional 4% articaine delivery by carpule syringe
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-22
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
编号:NCT03331848登记状态:入组前撤回企业 / 申办者:Prexton Therapeutics
药物 / 成分:Placebo oral capsule、PXT002331 - 20mg
登记的停止原因(原文):Business reasons
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-03-21
Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers
编号:NCT01275612登记状态:入组前撤回企业 / 申办者:Mario Negri Institute for Pharmacological Research
药物 / 成分:Mesenchymal stromal cell infusion
登记的停止原因(原文):Patients evaluated so far could not be enrolled because they did not meet the primary criterion of acute renal failure provided by the study protocol
查看官方原始记录 ↗